Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Return on Equity (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Return on Equity for 11 consecutive years, with 3.35% as the latest value for Q2 2025.

  • Quarterly Return on Equity rose 298.0% to 3.35% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 3.35% through Jun 2025, up 298.0% year-over-year, with the annual reading at 8.1% for FY2024, 362.0% down from the prior year.
  • Return on Equity hit 3.35% in Q2 2025 for Seres Therapeutics, down from 4.14% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 10.68% in Q1 2023 to a low of 8.67% in Q3 2023.
  • Historically, Return on Equity has averaged 0.3% across 5 years, with a median of 0.47% in 2021.
  • Biggest five-year swings in Return on Equity: soared 1149bps in 2023 and later tumbled -1121bps in 2024.
  • Year by year, Return on Equity stood at 0.42% in 2021, then plummeted by -1011bps to 4.67% in 2022, then skyrocketed by 126bps to 1.23% in 2023, then soared by 444bps to 6.68% in 2024, then tumbled by -50bps to 3.35% in 2025.
  • Business Quant data shows Return on Equity for MCRB at 3.35% in Q2 2025, 4.14% in Q1 2025, and 6.68% in Q4 2024.